Objective: Chronic lymphocytic leukemia (CLL) is an adult leukemia presented with clonal accumulation of lymphocytes. Immunophenotypic changes can be effective in predicting clinical course, the survival of patients, and determining first-line treatment. This is a study of the association between immunophenotypic markers with complete blood cell count (CBC) values and clinical parameters.
Results: Peripheral blood samples were collected from 35 newly diagnosed CLL patients. The expression of immunophenotypic markers and CBC were evaluated. Platelet counts and hemoglobin concentration had a significant, inverse association with Rai staging, modified Rai staging, Binet staging systems (all p< 0.001 in both parameters), and splenomegaly (p = 0.001 and 0.007, respectively). The platelet/lymphocyte ratio (PLR) had a significant, inverse association with Rai staging (p = 0.014), modified Rai staging (p = 0.024), Binet staging systems (p = 0.027), and splenomegaly (p = 0.033). However, CD38, CD25, and double-positive CD56/CD117 expression, group3 of innate lymphocyte cells (ILC3s), had no significant association with clinical parameters. In regression analysis, that ILC3s has an inverse correlation with neutrophil/lymphocyte ratio (r = -0.340, p = 0.046). Given that there is an inverse association between PLR and advanced clinical stages, it seems that PLR may have prognostic value in CLL.
This is a list of supplementary files associated with this preprint. Click to download.
Representative flow cytometry profiles of immunophenotypic markers expression in patients with CLL. a) Sample of CD38 and CD25 expression. b) Sample of double-positive CD56/CD117 expression.
Representative flow cytometry profiles of immunophenotypic markers expression in patients with CLL. a) Sample of CD38 and CD25 expression. b) Sample of double-positive CD56/CD117 expression.
A significant, negative correlation between double-positive CD56/CD117 expression with neutrophil/lymphocyte ration (NLR) (r = -0.340, p = 0.046) in CLL patients.
A non-significant, negative correlation between double-positive CD56/CD117 expression with platelet/lymphocyte ration (PLR) (r = -0.264, p = 0.125) in CLL patients.
Loading...
Posted 18 Aug, 2020
On 03 Sep, 2020
On 17 Aug, 2020
On 14 Aug, 2020
On 13 Aug, 2020
On 13 Aug, 2020
On 09 Aug, 2020
Received 01 Aug, 2020
On 24 Jul, 2020
On 20 Jul, 2020
Invitations sent on 20 Jul, 2020
On 15 Jul, 2020
On 13 Jul, 2020
On 11 Jul, 2020
Posted 18 Aug, 2020
On 03 Sep, 2020
On 17 Aug, 2020
On 14 Aug, 2020
On 13 Aug, 2020
On 13 Aug, 2020
On 09 Aug, 2020
Received 01 Aug, 2020
On 24 Jul, 2020
On 20 Jul, 2020
Invitations sent on 20 Jul, 2020
On 15 Jul, 2020
On 13 Jul, 2020
On 11 Jul, 2020
Objective: Chronic lymphocytic leukemia (CLL) is an adult leukemia presented with clonal accumulation of lymphocytes. Immunophenotypic changes can be effective in predicting clinical course, the survival of patients, and determining first-line treatment. This is a study of the association between immunophenotypic markers with complete blood cell count (CBC) values and clinical parameters.
Results: Peripheral blood samples were collected from 35 newly diagnosed CLL patients. The expression of immunophenotypic markers and CBC were evaluated. Platelet counts and hemoglobin concentration had a significant, inverse association with Rai staging, modified Rai staging, Binet staging systems (all p< 0.001 in both parameters), and splenomegaly (p = 0.001 and 0.007, respectively). The platelet/lymphocyte ratio (PLR) had a significant, inverse association with Rai staging (p = 0.014), modified Rai staging (p = 0.024), Binet staging systems (p = 0.027), and splenomegaly (p = 0.033). However, CD38, CD25, and double-positive CD56/CD117 expression, group3 of innate lymphocyte cells (ILC3s), had no significant association with clinical parameters. In regression analysis, that ILC3s has an inverse correlation with neutrophil/lymphocyte ratio (r = -0.340, p = 0.046). Given that there is an inverse association between PLR and advanced clinical stages, it seems that PLR may have prognostic value in CLL.
Loading...